Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Anja Vogt

Showing results (31-40 of 51) with videos related to

Pageof 6
Sort By:
Advances in Therapy|January 29, 2024
Evolocumab-Based LDL-C Management in High and Very High Cardiovascular Risk Patients in German Clinical Practice: The HEYMANS StudyMichael Lehrke, Anja Vogt, Volker Schettler, et al.
Vascular Pharmacology|March 27, 2019
Treatment with PCSK9 inhibitors reduces atherogenic VLDL remnants in a real-world studyTim Hollstein, Anja Vogt, Thomas Grenkowitz, et al.
Nuclear Medicine and Biology|July 2, 2019
Modelling the internalisation process of prostate cancer cells for PSMA-specific ligandsGordon Winter, Anja Vogt, Luis David Jiménez-Franco, et al.
Nature Clinical Practice. Cardiovascular Medicine|February 24, 2009
Longitudinal cohort study on the effectiveness of lipid apheresis treatment to reduce high lipoprotein(a) levels and prevent major adverse coronary eventsBeate R Jaeger, Yvonne Richter, Dorothea Nagel, et al.
Human Mutation|February 20, 2004
Molecular characterization of familial hypercholesterolemia in German and Greek patientsGeorge V Z Dedoussis, Janine Genschel, Bettina Bochow, et al.
Therapeutic Apheresis and Dialysis : Official Peer-Reviewed Journal of the International Society for Apheresis, the Japanese Society for Apheresis, the Japanese Society for Dialysis Therapy|December 5, 2022
The German Lipoprotein Apheresis Registry-Summary of the ninth annual reportVolker J J Schettler, Christian Peter, Thomas Zimmermann, et al.
Frontiers in Genetics|September 8, 2022
Efficacy of Long-Term Treatment of Autosomal Recessive Hypercholesterolemia With Lomitapide: A Subanalysis of the Pan-European Lomitapide StudyLaura D'Erasmo, Antonina Giammanco, Patrizia Suppressa, et al.
Therapeutic Apheresis and Dialysis : Official Peer-Reviewed Journal of the International Society for Apheresis, the Japanese Society for Apheresis, the Japanese Society for Dialysis Therapy|April 22, 2009
Single lipoprotein apheresis session improves cardiac microvascular function in patients with elevated lipoprotein(a): detection by stress/rest perfusion magnetic resonance imagingSteffen Bohl, Ursula Kassner, Rahel Eckardt, et al.
Journal of Clinical Lipidology|May 22, 2016
Alirocumab in patients with heterozygous familial hypercholesterolemia undergoing lipoprotein apheresis: Rationale and design of the ODYSSEY ESCAPE trialPatrick M Moriarty, Klaus G Parhofer, Stephan P Babirak, et al.
European Heart Journal|February 21, 2026
Pelacarsen and lipoprotein(a) apheresis in secondary prevention: the Lp(a)FRONTIERS APHERESIS trialKlaus G Parhofer, Ulrich Julius, Anna Laura Herzog, et al.
Pageof 6

Showing results (31-40 of 51) with videos related to

Sort By:
Pageof 6
Advances in Therapy|January 29, 2024
Evolocumab-Based LDL-C Management in High and Very High Cardiovascular Risk Patients in German Clinical Practice: The HEYMANS StudyMichael Lehrke, Anja Vogt, Volker Schettler, et al.
Vascular Pharmacology|March 27, 2019
Treatment with PCSK9 inhibitors reduces atherogenic VLDL remnants in a real-world studyTim Hollstein, Anja Vogt, Thomas Grenkowitz, et al.
Nuclear Medicine and Biology|July 2, 2019
Modelling the internalisation process of prostate cancer cells for PSMA-specific ligandsGordon Winter, Anja Vogt, Luis David Jiménez-Franco, et al.
Nature Clinical Practice. Cardiovascular Medicine|February 24, 2009
Longitudinal cohort study on the effectiveness of lipid apheresis treatment to reduce high lipoprotein(a) levels and prevent major adverse coronary eventsBeate R Jaeger, Yvonne Richter, Dorothea Nagel, et al.
Human Mutation|February 20, 2004
Molecular characterization of familial hypercholesterolemia in German and Greek patientsGeorge V Z Dedoussis, Janine Genschel, Bettina Bochow, et al.
Therapeutic Apheresis and Dialysis : Official Peer-Reviewed Journal of the International Society for Apheresis, the Japanese Society for Apheresis, the Japanese Society for Dialysis Therapy|December 5, 2022
The German Lipoprotein Apheresis Registry-Summary of the ninth annual reportVolker J J Schettler, Christian Peter, Thomas Zimmermann, et al.
Frontiers in Genetics|September 8, 2022
Efficacy of Long-Term Treatment of Autosomal Recessive Hypercholesterolemia With Lomitapide: A Subanalysis of the Pan-European Lomitapide StudyLaura D'Erasmo, Antonina Giammanco, Patrizia Suppressa, et al.
Therapeutic Apheresis and Dialysis : Official Peer-Reviewed Journal of the International Society for Apheresis, the Japanese Society for Apheresis, the Japanese Society for Dialysis Therapy|April 22, 2009
Single lipoprotein apheresis session improves cardiac microvascular function in patients with elevated lipoprotein(a): detection by stress/rest perfusion magnetic resonance imagingSteffen Bohl, Ursula Kassner, Rahel Eckardt, et al.
Journal of Clinical Lipidology|May 22, 2016
Alirocumab in patients with heterozygous familial hypercholesterolemia undergoing lipoprotein apheresis: Rationale and design of the ODYSSEY ESCAPE trialPatrick M Moriarty, Klaus G Parhofer, Stephan P Babirak, et al.
European Heart Journal|February 21, 2026
Pelacarsen and lipoprotein(a) apheresis in secondary prevention: the Lp(a)FRONTIERS APHERESIS trialKlaus G Parhofer, Ulrich Julius, Anna Laura Herzog, et al.
Pageof 6